5-[4-(6-ethoxycarbonyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione | 137786-87-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 5-[4-(6-ethoxycarbonyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)-benzyl]thiazolidine-2,4-dione
• 英文别名: 5-(4-(6-Ethoxycarbonyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl)thiazolidine-2,4-dione；[2-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] ethyl carbonate
• CAS: 137786-87-9
• 化学式: C₂₇H₃₁NO₇S
• 分子量: 513.612
• InChiKey: TUWVRIRVQCCGDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• Treatment and prophylaxis of pancreatitis
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0796618A1

  公开（公告）日：1997-09-24

  Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.

  胰岛素增敏剂，尤其是噻唑烷二酮化合物，如曲格列酮，可用于治疗和预防胰腺炎。
• Composition for use in the treatment and prevention of hyperuricemia
  申请人：Sankyo Company Limited

  公开号：EP0919232A1

  公开（公告）日：1999-06-02

  Insulin sensitivity enhancers, such as troglitazone, have the ability to treat and/or prevent hyperuricemia and may thus be used for the therapy or prophylaxis of such diseases as gout, urinary calculus, hyperuricemic nephropathy and Lesch-Nyhan syndrome.

  曲格列酮等胰岛素敏感性增强剂具有治疗和/或预防高尿酸血症的能力，因此可用于痛风、尿路结石、高尿酸血症肾病和莱希-尼汉综合征等疾病的治疗或预防。
• REMEDY FOR AUTOIMMUNE DISEASES
  申请人：Sankyo Company, Limited

  公开号：EP0953355A1

  公开（公告）日：1999-11-03

  A preventive or therapeutic agent for autoimmune diseases (excluding type I diabetes) contaning an insulin resistance improving substance as an active ingredient.

  一种预防或治疗自身免疫性疾病（I 型糖尿病除外）的制剂，含有一种改善胰岛素抵抗的物质作为活性成分。
• Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use
  申请人：Sankyo Company Limited

  公开号：EP0439321B1

  公开（公告）日：1995-03-15
• Methods and compositions for the treatment of neurodegenerative disorders
  申请人：Jin Xiaowei

  公开号：US20080044390A1

  公开（公告）日：2008-02-21

  The present invention features compositions, kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease.